

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2023/150688 A8

(43) International Publication Date
10 August 2023 (10.08.2023)

(51) International Patent Classification:

A61K 38/47 (2006.01) A61K 48/00 (2006.01)
C12N 15/86 (2006.01) A61P 3/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2023/061951

(88) Date of publication of the international search report:

28 September 2023 (28.09.2023)

(22) International Filing Date:

03 February 2023 (03.02.2023)

(48) Date of publication of this corrected version:

16 November 2023 (16.11.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/306,361 03 February 2022 (03.02.2022) US
63/402,850 31 August 2022 (31.08.2022) US

(15) Information about Correction:

see Notice of 16 November 2023 (16.11.2023)

(71) Applicant: **ASTELLAS GENE THERAPIES, INC.**

[US/US]; 225 Gateway Blvd., South San Francisco, CA
94080 (US).

(72) Inventors: **MOZAFFAR, Tahseen**; 200 S Manchester

Ave, #110, Orange, CA 92868 (US). **SMITH, Angela**; 600
California Street, 17th Floor, San Francisco, CA 94108
(US).

(74) Agent: **QUARTARARO, Justin, S.**; Clark & Elbing LLP,

101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF POMPE DISEASE

(57) Abstract: The present invention provides methods for treating co-morbid transaminasemia associated with a glycogen storage disorder. In certain embodiments, the invention provides methods for assessing readiness of a subject with Pompe disease for combination therapy with an anti-transaminitis agent.

WO 2023/150688 A8